Dyne Therapeutics (DYN)
(Real Time Quote from BATS)
$44.00 USD
+0.81 (1.88%)
Updated Jul 23, 2024 02:08 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DYN 44.00 +0.81(1.88%)
Will DYN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DYN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DYN
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
DYN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Other News for DYN
Buy Rating on Dyne Therapeutics Backed by Promising Clinical Data and Broad Therapeutic Potential of FORCE Platform
Dyne Therapeutics participates in a conference call with JPMorgan
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
Dyne announces new Pompe disease data showing potential of FORCE platform
Dynagreen Environmental Unveils New Board Structure